Wall Street Zen upgraded shares of Immuneering (NASDAQ:IMRX – Free Report) from a strong sell rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.
A number of other analysts have also issued reports on IMRX. UBS Group set a $14.00 target price on shares of Immuneering in a research note on Thursday, August 6th. Chardan Capital raised Immuneering to a “strong-buy” rating in a research note on Monday, August 3rd. Mizuho set a $11.00 price objective on Immuneering in a report on Thursday, October 29th. HC Wainwright reaffirmed a “buy” rating on shares of Immuneering in a research note on Friday, October 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and a consensus price target of $15.67.
View Our Latest Analysis on IMRX
Immuneering Trading Down 2.0%
Immuneering (NASDAQ:IMRX – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.06). As a group, equities analysts forecast that Immuneering will post -1.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Immuneering
Several institutional investors have recently bought and sold shares of IMRX. Integrated Wealth Concepts LLC bought a new position in shares of Immuneering in the second quarter valued at approximately $34,000. HighTower Advisors LLC raised its holdings in Immuneering by 4.7% in the 3rd quarter. HighTower Advisors LLC now owns 150,286 shares of the company’s stock worth $615,000 after acquiring an additional 6,800 shares during the period. American Century Companies Inc. lifted its position in Immuneering by 15.4% during the 3rd quarter. American Century Companies Inc. now owns 68,751 shares of the company’s stock worth $282,000 after acquiring an additional 9,193 shares during the last quarter. Palumbo Wealth Management LLC grew its holdings in Immuneering by 51.6% in the 3rd quarter. Palumbo Wealth Management LLC now owns 28,932 shares of the company’s stock valued at $118,000 after buying an additional 9,849 shares during the last quarter. Finally, VestGen Advisors LLC lifted its position in shares of Immuneering by 100.0% in the 3rd quarter. VestGen Advisors LLC now owns 20,002 shares of the company’s stock worth $82,000 after acquiring an additional 10,002 shares during the period. 67.65% of the stock is currently owned by institutional investors.
About Immuneering
Immuneering Corporation is a clinical-stage biotechnology company developing medicines for cancer. The company uses computational biology and drug-discovery approaches to study disease patterns and identify potential therapeutic targets, with a focus on the MAPK signaling pathway, which is involved in many cancers. Its lead drug candidate, atebimetinib (IMM-1-104), is an oral investigational therapy designed to inhibit MEK proteins and disrupt MAPK signaling. Immuneering is evaluating this candidate for solid tumors, including pancreatic cancer, and is advancing additional drug candidates aimed at cancer-related pathways.
Further Reading
- Five stocks we like better than Immuneering
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
